UNSPSC 51412404: Carbocromen hydrochloride

This classification denotes a vasodilating agent with the molecular formula C20H27NO5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 52C937V399, chemically known as acetic acid, ((3-(2-(diethylamino)ethyl)-4-methyl-2-oxo-2h-1-benzopyran-7-yl)oxy)-, ethyl ester, hydrochloride but more generally known as carbocromen hydrochloride, which bears US NIH Compound Identifier 12603. European Medicines Agency schedules Carbocromen hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01048MIG.

Most nations, for tariff and trade purposes, schedule carbocromen hydrochloride under HS 29322985. SMILES: CCN(CC)CCC1C(C2CCC(CC2OC1=O)OCC(=O)OCC)C.CL.

UNSPSC 51412404 Carbocromen hydrochloride is a Commodity code representing pharmaceutical active ingredients and finished medications purchased by state and local public health agencies, primarily fire rescue services, state health departments, and cooperative purchasing alliances that procure medications for emergency medical services, public health programs, and state employee health plans. State and local governments buy specific pharmaceutical formulations under this code — typically advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products distributed through authorized wholesalers or direct-to-end-user supply chains. Recent solicitations show issuing bodies spanning municipal fire departments (city purchasing offices), state health and human services commissions, and multistate cooperative purchasing vehicles serving state agencies and participating local government facilities across multiple jurisdictions. Vendors must meet stringent compliance requirements including FDA registration, current Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, expiration-date minimums (typically nine to twelve months from acceptance), and OSHA Safety Data Sheet documentation; many solicitations also mandate comprehensive insurance coverage, electronic data interchange capability, and relationships with authorized pharmaceutical wholesalers.

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications (Labetalol HCI, Epinephrine 1:10,000, Adenosine, Diltiazem vials) for Tampa Fire Rescue with a due date of April 8, 2026, and an estimated contract value of $40,000; the solicitation carried a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (administered by the Minnesota Department of Administration) issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., with proposals due March 26, 2026, and effective contract dates beginning July 1, 2026; MMCAP's procurement served participating state and local government facilities in Minnesota and Oregon.